179323-60-5

Basic information

• Product Name: 1-PYRAZIN-2-YL-ETHYLAMINE
• Synonyms: 1-PYRAZIN-2-YL-ETHYLAMINE;1-(Pyrazin-2-yl)ethanamine;2-Pyrazinemethanamine, .alpha.-methyl-;1-(pyrazin-2-yl)ethan-1-aMine;alpha-Methyl-2-pyrazinemethanamine;1-(Pyrazin-2-yl)
• CAS NO: 179323-60-5
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.16
• Mol File: 179323-60-5.mol

Chemical Properties

• Boiling Point: 215.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.088±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.19±0.40(Predicted)
• CAS DataBase Reference: 1-PYRAZIN-2-YL-ETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PYRAZIN-2-YL-ETHYLAMINE(179323-60-5)
• EPA Substance Registry System: 1-PYRAZIN-2-YL-ETHYLAMINE(179323-60-5)

Safety Data

• Hazardous Substances Data: 179323-60-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-PYRAZIN-2-YL-ETHYLAMINE is used as a potential beta3-adrenoceptor agonist for its ability to activate beta3-adrenergic receptors. This activation can lead to various therapeutic effects, such as enhancing metabolic processes, improving insulin sensitivity, and promoting weight loss. Its potential use in the development of drugs for obesity, type 2 diabetes, and other metabolic disorders highlights its significance in the pharmaceutical industry.

Upstream product

• 22047-25-2 acetylpyrazine 

Downstream Products

• 1258950-55-8 4'-Methyl-5-(2-oxo-benzooxazol-3-yl)-biphenyl-3-carboxylic acid (1-pyrazin-2-yl-ethyl)-amide 

Relevant articles and documents

P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted thiadiazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula 1: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted phenyl or optionally substituted pyridinyl, and R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: wherein R1 is optionally substituted imidazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.

Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted pyrazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted triazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.